John Chaney, MD
Pulmonary Disease · Fort Walton Beach, FLNPI 1346270592
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 72.4% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $10,693 and has fallen 80.9% since, to $2,044 in 2025.
Across 145 payments — averaging $153.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$16K
- Johnson & Johnson$2K
- Medical Device Business Services, Inc.$2K
- Electromed, Inc.$892
- Jazz Pharmaceuticals Inc.$132
- Grifols USA, LLC$116
- plus $607 from 18 others
What the payments were for
- Consulting fees$8,01636%
- Speaking & faculty fees$6,55030%
- Travel & lodging$4,71021%
- Food & beverage$2,92513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 34 | $16,076 |
| Johnson & Johnson | 18 | $2,377 |
| Medical Device Business Services, Inc. | 8 | $2,001 |
| Electromed, Inc. | 43 | $892 |
| Jazz Pharmaceuticals Inc. | 6 | $132 |
| Grifols USA, LLC | 6 | $116 |
| Dexcom, Inc. | 2 | $98 |
| Insmed, Inc. | 2 | $57 |
| Astellas Pharma US Inc | 3 | $55 |
| Sanofi | 3 | $51 |
| GSK | 3 | $49 |
| Inspire Medical Systems, Inc. | 2 | $43 |
| AstraZeneca | 3 | $40 |
| Philips North America LLC | 2 | $33 |
| Boston Scientific | 1 | $25 |
| Coaptech, Inc. | 1 | $22 |
| Watermark Medical, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Auris Health, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Inogen, Inc. | 1 | $16 |
| Resmed Corp | 1 | $14 |
| Fisher & Paykel Healthcare Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MONARCH$2,744
- Monarch Platform$1,158
- OFEV$807
- SMARTVEST$250
How this compares
$22,201 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 23 | $25 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Fort Walton Beach
- Luke Simon YuhicoFort Walton Beach$135K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.